BLOOD Centers Act

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5791 Introduced in House (IH)]

<DOC>

119th CONGRESS
  1st Session
                                H. R. 5791

 To direct the Secretary of Health and Human Services, acting through
 the Commissioner of Food and Drugs, to establish an expedited process
 for the approval of certain biologics license application supplements
               for blood centers, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            October 17, 2025

  Mr. Wied (for himself, Ms. Schrier, and Mr. Tiffany) introduced the
   following bill; which was referred to the Committee on Energy and
                                Commerce

_______________________________________________________________________

                                 A BILL

 To direct the Secretary of Health and Human Services, acting through
 the Commissioner of Food and Drugs, to establish an expedited process
 for the approval of certain biologics license application supplements
               for blood centers, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Boosting Lifesaving Operations,
Opening Donation Centers Act'' or the ``BLOOD Centers Act''.

SEC. 2. EXPEDITED PROCESS FOR APPROVAL OF CERTAIN BLA SUPPLEMENTS FOR
              BLOOD CENTERS.

    (a) Establishment.--Not later than 180 days after the date of
enactment of this Act, the Secretary, acting pursuant to section
351(a)(2) of the Public Health Service Act (42 U.S.C. 262(a)(2)), shall
establish an expedited process for the approval of a supplemental
application submitted by the owner or operator of a blood center
seeking to add an apheresis collection device to an existing BLA
license at a location not previously licensed for such a device.
    (b) Deadline.--Under the expedited procedure, the Secretary shall
approve a supplemental application described in subsection (a) not
later than 30 days after the date of submission of the application
unless the Secretary makes a showing that there is--
            (1) a specific concern for the safety, purity, or potency
        of products produced at the specific location subject to the
        supplemental application; or
            (2) a systemic failure by the owner or operator to meet
        standards designed to ensure the continued safety, purity, and
        potency of products produced at other locations under a
        biologics license.
    (c) Applicability.--The expedited procedure shall apply with
respect to a supplemental application described in subsection (a) if
the owner or operator that submits the application--
            (1) holds a biologics license for at least one blood center
        site; and
            (2)(A) has been approved for a biologics license at 3 or
        more Food and Drug Administration registered locations under
        the biologics license referred to in paragraph (1); or
            (B) is accredited and in good standing for blood collection
        by an accreditation organization with standards that meet or
        exceed, as determined by the Secretary, all applicable
        regulatory requirements for blood collections.
    (d) Definitions.--In this section:
            (1) BLA.--The term ``BLA'' means a biologics license
        application.
            (2) Blood center.--The term ``blood center'' means a human
        blood donation center.
            (3) Expedited procedure.--The term ``expedited procedure''
        means the expedited procedure to be established under
        subsection (a).
            (4) Secretary.--The term ``Secretary'' means the Secretary
        of Health and Human Services acting through the Commissioner of
        Food and Drugs.
                                 <all>